Dr. Venkat R. Nimmagadda, MD

Dr. Nimmagadda practices at Eufaula Dialysis in Columbus, Georgia.

Dr. Nimmagadda's NPI, 1043267917, was assigned on May 27, 2006. Dr. Nimmagadda holds Alabama license 27452.

Dr. Nimmagadda's primary practice is Eufaula Dialysis, at 6228 Bradley Park Dr, Columbus, GA 31904 in Muscogee County. The practice phone is (334) 688-0806.

Dr. Nimmagadda's primary practice is Eufaula Dialysis in Columbus, Georgia. Dr. Nimmagadda is also affiliated with Southeast Health Medical Center. The medical group on file is Medical Center Barbour Hospitalist. Dmand AI also links Dr. Nimmagadda to 4 more hospitals, 3 dialysis centers, 3 medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nimmagadda practices, 10 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Nimmagadda's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Nimmagadda is licensed in Alabama.

Dmand AI lists acute kidney failure, acute respiratory failure, anemia, chest pain, chronic hypertension, chronic kidney disease, electrolyte disorders and enlarged prostate among the conditions Dr. Nimmagadda treats.

CMS data shows 2,121 Medicare services from Dr. Nimmagadda across 14 procedure codes in 2024, for 540 Medicare patients. Medicare paid $200,977 for them.

CMS counts 540 Medicare patients who saw Dr. Nimmagadda in 2024. The largest group is 75 to 84, with 205 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 27% are also on Medicaid. Their average risk score is 3.33, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Nimmagadda's median patient age at 73, with 53% women.

In 2024, Dr. Nimmagadda wrote 2,283 Medicare Part D claims for 503 patients. 87% of them were for generic drugs. CMS names the drug for 1,985 of them, across 44 drugs with 11 or more claims each, at $280,541 in total drug cost. In 2023, CMS named 2,198 claims across 47 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Nimmagadda for performance year 2024, reported individually. Dr. Nimmagadda accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 70 general payments to Dr. Nimmagadda from 18 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 51% of the total. Akebia Therapeutics Inc paid the most, $4,629.

Dmand AI lists 1 award for Dr. Nimmagadda, most recently CMS Stage 1 2012 in 2012.

Dr. Nimmagadda is in network with 16 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.